scholarly journals The Role of Vitamin D in Disease Progression in Early Parkinson’s Disease

2017 ◽  
Vol 7 (4) ◽  
pp. 669-675 ◽  
Author(s):  
Isobel Sleeman ◽  
Terry Aspray ◽  
Rachael Lawson ◽  
Shirley Coleman ◽  
Gordon Duncan ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Vitamin D ◽  
Parkinson's Disease ◽  
Disease Progression ◽  
Early Parkinson’S Disease

Transcranial magnetic stimulation follow-up study in early Parkinson's disease: A decline in compensation with disease progression?

2015 ◽  
Vol 30 (8) ◽  
pp. 1098-1106 ◽  
Author(s):  
Maja Kojovic ◽  
Panagiotis Kassavetis ◽  
Matteo Bologna ◽  
Isabel Pareés ◽  
Ignacio Rubio-Agusti ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Transcranial Magnetic Stimulation ◽  
Disease Progression ◽  
Magnetic Stimulation ◽  
Follow Up Study ◽  
Early Parkinson’S Disease

scholarly journals Linking COVID-19 and Parkinson's disease: Targeting the role of Vitamin-D

2021 ◽  
Author(s):  
Tapan Behl ◽  
Sachin Kumar ◽  
Aayush Sehgal ◽  
Sukhbir Singh ◽  
Neelam Sharma ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Vitamin D ◽  
Parkinson's Disease

scholarly journals Arylsulfatase A (ASA) in Parkinson’s Disease: From Pathogenesis to Biomarker Potential

2020 ◽  
Vol 10 (10) ◽  
pp. 713
Author(s):  
Efthalia Angelopoulou ◽  
Yam Nath Paudel ◽  
Chiara Villa ◽  
Christina Piperi
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Disease Progression ◽  
Neurodegenerative Disorder ◽  
In Vivo Studies ◽  
Arylsulfatase A ◽  
Lysosomal Storage ◽  
Potential Implication

Parkinson’s disease (PD), the second most common neurodegenerative disorder after Alzheimer’s disease, is a clinically heterogeneous disorder, with obscure etiology and no disease-modifying therapy to date. Currently, there is no available biomarker for PD endophenotypes or disease progression. Accumulating evidence suggests that mutations in genes related to lysosomal function or lysosomal storage disorders may affect the risk of PD development, such as GBA1 gene mutations. In this context, recent studies have revealed the emerging role of arylsulfatase A (ASA), a lysosomal hydrolase encoded by the ARSA gene causing metachromatic leukodystrophy (MLD) in PD pathogenesis. In particular, altered ASA levels have been detected during disease progression, and reduced enzymatic activity of ASA has been associated with an atypical PD clinical phenotype, including early cognitive impairment and essential-like tremor. Clinical evidence further reveals that specific ARSA gene variants may act as genetic modifiers in PD. Recent in vitro and in vivo studies indicate that ASA may function as a molecular chaperone interacting with α-synuclein (SNCA) in the cytoplasm, preventing its aggregation, secretion and cell-to-cell propagation. In this review, we summarize the results of recent preclinical and clinical studies on the role of ASA in PD, aiming to shed more light on the potential implication of ASA in PD pathogenesis and highlight its biomarker potential.

scholarly journals Role of Corpus Callosum Volumetry in Differentiating the Subtypes of Progressive Supranuclear Palsy and Early Parkinson's Disease

2017 ◽  
Vol 4 (4) ◽  
pp. 552-558 ◽  
Author(s):  
Abhishek Lenka ◽  
Shaik Afsar Pasha ◽  
Sandhya Mangalore ◽  
Lija George ◽  
Ketan Ramakant Jhunjhunwala ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Corpus Callosum ◽  
Progressive Supranuclear Palsy ◽  
Early Parkinson’S Disease
Sign in / Sign up

Export Citation Format

Share Document